Murton, Molly
Drane, Emma
Jarrett, James
Cornely, Oliver A.
Soriano, Alex http://orcid.org/0000-0002-9374-0811
Funding for this research was provided by:
Gilead Sciences Europe Ltd
Article History
Received: 5 May 2022
Accepted: 20 September 2022
First Online: 12 October 2022
Declarations
:
: MM and ED: Employees of Costello Medical. JJ: Employee of Gilead Sciences, Inc. OC: Grants or contracts: Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; consulting fees: Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; honoraria for lectures: Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; payment for expert testimony: Cidara; participation on a Data Safety Monitoring Board or Advisory Board: Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Shionogi; a patent from the German Patent and Trade Mark Office (DE 10 2021 113 007.7); other interests: DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley. AS: Grants: Pfizer, Gilead; fees for lectures and advisory boards: Pfizer, MSD, Gilead, Angelini, Shionogi, and Menarini. The authors acknowledge Yasemin Hasimoglu, BA, from Costello Medical, US, for medical writing and editorial assistance based on the authors’ input and direction. This study was funded by Gilead Sciences Europe Ltd.